Edition:
India

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

125.41USD
2:29am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$125.41
Open
$125.24
Day's High
$126.60
Day's Low
$124.85
Volume
107,325
Avg. Vol
206,924
52-wk High
$169.58
52-wk Low
$112.15

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $5,381.27
Shares Outstanding(Mil.): 43.44
Dividend: --
Yield (%): --

Financials

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

14 Nov 2017

BRIEF-United Therapeutics Corp reports third quarter 2017 financial results

* United Therapeutics Corporation reports third quarter 2017 financial results

25 Oct 2017

BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

23 Oct 2017

BRIEF-United Therapeutics Corp reports Q2 EPS non-GAAP $4.37

* United Therapeutics Corporation reports second quarter 2017 financial results

27 Jul 2017

BRIEF-United Therapeutics enters into agreement with Citibank relating to share repurchase program

* United Therapeutics Corp - on May 31, 2017, co entered into agreement with Citibank, N.A. relating to a collared accelerated share repurchase program

01 Jun 2017

Earnings vs. Estimates